RT Journal Article
T1 Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination in Kidney Transplant Recipients.
A1 Mazuecos, Auxiliadora
A1 Villanego, Florentino
A1 Zarraga, Sofia
A1 Lopez, Veronica
A1 Oppenheimer, Federico
A1 Llinas-Mallol, Laura
A1 Hernandez, Ana M
A1 Rivas, Alba
A1 Ruiz-Fuentes, Maria C
A1 Toapanta, Nestor G
A1 Jimenez, Carlos
A1 Cabello, Sheila
A1 Beneyto, Isabel
A1 Aladren, Maria J
A1 Rodriguez-Benot, Alberto
A1 Canal, Cristina
A1 Molina, Maria
A1 Perez-Flores, Isabel
A1 Saura, Isabel M
A1 Gavela, Eva
A1 Franco, Antonio
A1 Lorenzo, Inmaculada
A1 Galeano, Cristina
A1 Tabernero, Guadalupe
A1 Perez-Tamajon, Lourdes
A1 Martin-Moreno, Paloma L
A1 Fernandez-Giron, Fernando
A1 Siverio, Orlando
A1 Labrador, Pedro J
A1 De Arriba, Gabriel
A1 Simal, Fernando
A1 Cruzado, Leonidas
A1 Moina, Inigo
A1 Alcalde, Guillermo
A1 Sanchez-Alvarez, Emilio
A1 Pascual, Julio
A1 Crespo, Marta
K1 2019-nCoV Vaccine mRNA-1273
K1 BNT162 Vaccine
K1 COVID-19
K1 COVID-19 Vaccines
AB The clinical effectiveness of coronavirus disease 2019 (COVID-19) vaccination in kidney transplant (KT) recipients is lower than in the general population. From April to October 2021, 481 KT recipients with COVID-19, included in the Spanish Society of Nephrology COVID-19 Registry, were analyzed. Data regarding vaccination status and vaccine type were collected, and outcomes of unvaccinated or partially vaccinated patients (n = 130) were compared with fully vaccinated patients (n = 351). Clinical picture was similar and survival analysis showed no differences between groups: 21.7% of fully vaccinated patients and 20.8% of unvaccinated or partially vaccinated died (P = 0.776). In multivariable analysis, age and pneumonia were independent risk factors for death, whereas vaccination status was not related to mortality. These results remained similar when we excluded patients with partial vaccination, as well as when we analyzed exclusively hospitalized patients. Patients vaccinated with mRNA-1273 (n = 213) showed a significantly lower mortality than those who received the BNT162b2 vaccine (n = 121) (hazard ratio: 0.52; 95% confidence interval, 0.31-0.85; P = 0.010). COVID-19 severity in KT patients has remained high and has not improved despite receiving 2 doses of the mRNA vaccine. The mRNA-1273 vaccine shows higher clinical effectiveness than BNT162b2 in KT recipients with breakthrough infections. Confirmation of these data will require further research taking into account the new variants and the administration of successive vaccine doses.
PB Lippincott Williams & Wilkins
YR 2022
FD 2022-02-01
LK http://hdl.handle.net/10668/19872
UL http://hdl.handle.net/10668/19872
LA en
NO Mazuecos A, Villanego F, Zarraga S, López V, Oppenheimer F, Llinàs-Mallol L, et al. Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination in Kidney Transplant Recipients. Transplantation. 2022 Jul 1;106(7):1430-1439
DS RISalud
RD Apr 19, 2025